Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...

Podrobná bibliografie
Hlavní autoři:	Peyrin-Biroulet, L, Sandborn, W, Sands, B, Reinisch, W, Bemelman, W, Bryant, R, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P, Loftus, E, Marteau, P, Munkholm, P, Murdoch, T, Ordás, I, Panaccione, R, Riddell, R, Ruel, J, Rubin, D, Samaan, M, Siegel, C, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J
Médium:	Journal article
Jazyk:	English
Vydáno:	Nature Publishing Group 2015

Podobné jednotky

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
Autor: Sandborn, W, a další
Vydáno: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
Autor: Peyrin-Biroulet, L, a další
Vydáno: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
Autor: Danese, S, a další
Vydáno: (2015)

Development of an index to define overall disease severity in IBD
Autor: Siegel, C, a další
Vydáno: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
Autor: D'Haens, G, a další
Vydáno: (2009)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
Autor: Remo Panaccione, a další
Vydáno: (2015-12-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
Autor: Jairath, V, a další
Vydáno: (2016)

Development of the Crohn's disease digestive damage score, the Lemann score.
Autor: Pariente, B, a další
Vydáno: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
Autor: Reinisch, W, a další
Vydáno: (2018)

Evolving concepts in phases I and II drug development for Crohn's Disease
Autor: Jairath, V, a další
Vydáno: (2016)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
Autor: Khanna, R, a další
Vydáno: (2023)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
Autor: Travis, S, a další
Vydáno: (2013)

Biosimilars in IBD: hope or expectation?
Autor: Gecse, K, a další
Vydáno: (2013)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
Autor: Vuitton, L, a další
Vydáno: (2017)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Autor: Clark, M, a další
Vydáno: (2007)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
Autor: Gasche, C, a další
Vydáno: (2000)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
Autor: Travis, S, a další
Vydáno: (2013)

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
Autor: Travis, S, a další
Vydáno: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Autor: Panaccione, R, a další
Vydáno: (2019)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
Autor: Travis, S, a další
Vydáno: (2012)

Review article: defining remission in ulcerative colitis.
Autor: Travis, S, a další
Vydáno: (2011)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
Autor: Travis, S, a další
Vydáno: (2008)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Autor: Laurent Peyrin-Biroulet, a další
Vydáno: (2024-01-01)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Autor: Sandborn, W, a další
Vydáno: (2015)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Autor: Colombel, J, a další
Vydáno: (2017)

CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease
Autor: Ma, C, a další
Vydáno: (2022)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Autor: Travis, S, a další
Vydáno: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Autor: Travis, S, a další
Vydáno: (2017)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Autor: D'Haens, G, a další
Vydáno: (2011)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Autor: Van Assche, G, a další
Vydáno: (2011)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Autor: Travis, S, a další
Vydáno: (2014)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
Autor: Lichtenstein, G, a další
Vydáno: (2015)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
Autor: D'Haens, G, a další
Vydáno: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
Autor: Yzet, C, a další
Vydáno: (2019)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
Autor: Gottlieb, K, a další
Vydáno: (2015)

The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease
Autor: Horrigan, JM, a další
Vydáno: (2023)

Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model
Autor: Wildenberg, M, a další
Vydáno: (2017)

Antieosinophil Therapeutics
Autor: Straumann, A, a další
Vydáno: (2013)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
Autor: Samaan, MA, a další
Vydáno: (2018)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
Autor: Travis, S, a další
Vydáno: (2017)